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Rosacea subtypes and associated  
clinical features
In this cross-sectional study of a rosacea cohort from a 
North German community, Tan et al. report demographics, 
rosacea subtypes, primary and secondary rosacea-asso-
ciated features and other clinical assessments. The study 
objective was to identify associations between the four 
main rosacea subtypes. Significant differences were iden-
tified between erythemotelangiectatic and inflammatory 
papulopustular rosacea for rosacea-associated features. 
Br J Dermatol 2013; 169: 555–562.
Risk factors for polysensitization  
to contact allergens
This study from Germany used a statistical approach to analyse 
the phenomenon of contact sensitization to three or more 
unrelated haptens of the baseline patch test series. Negative 
binomial hurdle regression was applied to patch-test data for 
126,878 patients. The authors describe how the presented data 
point to risk factors that need to be considered in future poly-
sensitization research. Br J Dermatol 2013; 169: 611–617.
HLA-B*58:01 in cutaneous adverse drug 
reactions from allopurinol
Gonçalo et al. report on a series of 31 Portuguese patients 
with cutaneous adverse drug reactions from allopurinol. 
Human leucocyte antigen (HLA) genotyping for these 
patients was compared with that for 25 allopurinol-toler-
ant individuals and a control population. A high frequency 
of HLA-B*58:01 is reported. The authors discuss the role 
of preallopurinol HLA typing for B*58:01 in European 
populations. Br J Dermatol 2013; 169: 665–670.
Survival rate for anti-TNF-α treatments for 
psoriasis in routine dermatological practice
Esposito et al. report survival rates for antitumour necrosis 
factor-α treatments for psoriasis in this multicentre obser-
vational study from Italy. The study included 650 adult 
patients from three academic centres treated with adalim-
umab, etanercept and infliximab for at least 3 months. The 
main reason for drug discontinuation was loss of efficacy. 
Br J Dermatol 2013; 169: 671–677.
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